Company intelligence / Profile preview

3Spine

Chattanooga, Tennessee, United States3spine.com ↗

Ownership: Private
Development stage: Phase 2

Overview

3Spine has completed over 300 surgeries in pivotal FDA Investigational Device Exemption (IDE) trials for its MOTUS lumbar total joint replacement system. Clinical pilot studies showed significant improvements in patient-reported outcomes compared to traditional spinal fusion, including a 2.4x improvement in Oswestry Disability Index Substantial Clinical Benefit at one year. The company has received Breakthrough Device Designation from the FDA and aims to offer an alternative standard of care for patients with chronic low back pain

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

MOTUS

Phase 2

Indications: Lumbar spinal disorders, Degenerative disc disease

Partnerships

MCRA (clinical research organization/CRO partner)

Beyond the preview

Go deeper on 3Spine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3Spine.

Explore the full profile